专题：HIV-related health complications and treatments

This cluster of papers explores the impact of HIV infection, antiretroviral therapy, inflammation, metabolic abnormalities, and aging on cardiovascular health. It covers a wide range of topics including myocardial infarction, lipodystrophy, bone mineral density, insulin resistance, and the association between HIV infection and various cardiovascular diseases. The research also delves into the effects of specific antiretroviral drugs on cardiovascular risk factors and provides insights into the management of metabolic complications associated with HIV-1 infection.
最新文献
Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial

article Full Text OpenAlex

Utilizing pharmacy refill data to predict loss to follow-up among people living with HIV in Manyara region of Tanzania

article Full Text OpenAlex

Associations Between Sustained Methamphetamine/Amphetamine Use and Left Ventricular Dysfunction in a Cohort of Women Living With and Without HIV

article Full Text OpenAlex

Comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012–2020

article Full Text OpenAlex

Rethinking screening strategies for non-obese individuals at risk for MASLD: a clinical perspective on metabolic vulnerability

article Full Text OpenAlex

Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease

article Full Text OpenAlex

Type 2 diabetes in people living with HIV: epidemiology, mechanisms, sex differences and early-life determinants

article Full Text OpenAlex

Frailty in People with HIV Is Linked to Inflammation, Bone Health, and T-Cell Exhaustion

article Full Text OpenAlex

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

article Full Text OpenAlex

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial

article Full Text OpenAlex

近5年高被引文献
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies

article Full Text OpenAlex 412 FWCI81.0389

Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

article Full Text OpenAlex 403 FWCI142.8607

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

article Full Text OpenAlex 367 FWCI146.546

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

review Full Text OpenAlex 228 FWCI46.2149

Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis

article Full Text OpenAlex 202 FWCI37.7245

HIV infection

review Full Text OpenAlex 186 FWCI37.8963

Folic Acid, Folinic Acid, 5 Methyl TetraHydroFolate Supplementation for Mutations That Affect Epigenesis through the Folate and One-Carbon Cycles

review Full Text OpenAlex 173 FWCI27.1944

Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel

letter Full Text OpenAlex 141 FWCI55.9031

Monocyte-derived macrophages contain persistent latent HIV reservoirs

article Full Text OpenAlex 136 FWCI19.5392

Cognitive impairment in people living with HIV: consensus recommendations for a new approach

review Full Text OpenAlex 133 FWCI19.1647